T-1101 Receives FDA Approval to Advance to Phase II Clinical Trial, Marking a Significant Milestone
Taivex announced that T-1101 has received approval from the U.S. Food and Drug Administration (FDA) to advance to Phase II clinical trials. This trial will further evaluate the safety and efficacy of T-1101 in patients with neuroendocrine tumors (NET), laying a solid foundation for future regulatory submissions. T-1101 is the first-in-class oral small-molecule inhibitor …